JP2018198596A5 - - Google Patents

Download PDF

Info

Publication number
JP2018198596A5
JP2018198596A5 JP2018128111A JP2018128111A JP2018198596A5 JP 2018198596 A5 JP2018198596 A5 JP 2018198596A5 JP 2018128111 A JP2018128111 A JP 2018128111A JP 2018128111 A JP2018128111 A JP 2018128111A JP 2018198596 A5 JP2018198596 A5 JP 2018198596A5
Authority
JP
Japan
Prior art keywords
pad4
antibody according
antibody
seq
pad4 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018128111A
Other languages
English (en)
Japanese (ja)
Other versions
JP6675739B2 (ja
JP2018198596A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018198596A publication Critical patent/JP2018198596A/ja
Publication of JP2018198596A5 publication Critical patent/JP2018198596A5/ja
Application granted granted Critical
Publication of JP6675739B2 publication Critical patent/JP6675739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018128111A 2015-03-06 2018-07-05 新規抗pad4抗体 Active JP6675739B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015044518 2015-03-06
JP2015044518 2015-03-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017505334A Division JP6369922B2 (ja) 2015-03-06 2016-03-07 新規抗pad4抗体

Publications (3)

Publication Number Publication Date
JP2018198596A JP2018198596A (ja) 2018-12-20
JP2018198596A5 true JP2018198596A5 (enExample) 2019-04-18
JP6675739B2 JP6675739B2 (ja) 2020-04-01

Family

ID=56880525

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017505334A Active JP6369922B2 (ja) 2015-03-06 2016-03-07 新規抗pad4抗体
JP2018128111A Active JP6675739B2 (ja) 2015-03-06 2018-07-05 新規抗pad4抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017505334A Active JP6369922B2 (ja) 2015-03-06 2016-03-07 新規抗pad4抗体

Country Status (5)

Country Link
US (3) US11447569B2 (enExample)
EP (2) EP4223786A3 (enExample)
JP (2) JP6369922B2 (enExample)
ES (1) ES2952132T3 (enExample)
WO (1) WO2016143753A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4223786A3 (en) 2015-03-06 2023-08-16 Public University Corporation Yokohama City University Novel anti-pad4 antibodies
SG11202002481RA (en) 2017-09-19 2020-04-29 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing gene expression in eukaryotic cells
JPWO2019131769A1 (ja) * 2017-12-26 2021-02-12 公立大学法人名古屋市立大学 新規抗pad4抗体
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
CN111733151B (zh) * 2020-07-13 2021-11-12 山东新创生物科技有限公司 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用
JP7812367B2 (ja) * 2020-08-10 2026-02-09 インテグラル・モレキュラー・インコーポレイテッド 抗体ライブラリーを作製するための方法および組成物ならびにそれから単離された抗体
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
AU2022260698A1 (en) * 2021-04-21 2023-11-09 Oxford University Innovation Limited Method and composition
AU2023312054A1 (en) * 2022-07-22 2025-01-23 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024133161A1 (en) 2022-12-19 2024-06-27 Astrazeneca Ab Treatment of autoimmune disease
EP4709764A2 (en) * 2023-05-05 2026-03-18 The Johns Hopkins University Human monoclonal antibodies for treating subjects suffering from pulmonary fibrosis
KR20260041867A (ko) 2023-07-21 2026-03-27 브리스톨-마이어스 스큅 컴퍼니 Pad4 조정제의 시트룰린화 및 활성을 평가하는 방법
WO2025122927A1 (en) * 2023-12-06 2025-06-12 Integral Molecular, Inc. Antibodies directed to claudin 18.2, including bispecific formats thereof
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4304274B2 (ja) 2004-03-04 2009-07-29 国立大学法人広島大学 ニワトリ−ヒトキメラ抗体発現用ベクターおよびこれを用いたニワトリ−ヒトキメラ抗体生産方法、並びにその利用
WO2005085438A1 (ja) 2004-03-09 2005-09-15 Nagoya Industrial Science Research Institute ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
JP5252339B2 (ja) * 2007-12-25 2013-07-31 地方独立行政法人東京都健康長寿医療センター Pad4及び抗pad4抗体の測定方法並びに関節リウマチの検出方法
US20130101611A1 (en) * 2009-11-25 2013-04-25 The Johns Hopkins University Citrullination of human peptidylarginine deiminase 4 (pad-4) regulates its function and immunogenicity
WO2012026309A1 (ja) 2010-08-23 2012-03-01 公立大学法人横浜市立大学 抗pad4抗体医薬の創成
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
EP4223786A3 (en) 2015-03-06 2023-08-16 Public University Corporation Yokohama City University Novel anti-pad4 antibodies
WO2016155745A1 (en) * 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies

Similar Documents

Publication Publication Date Title
JP2020501532A5 (enExample)
JP2017160222A5 (enExample)
JP2017113019A5 (enExample)
JP2018193386A5 (enExample)
JP2012526542A5 (enExample)
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
RU2019118359A (ru) Антитело к cd73 человека
JP2009531283A5 (enExample)
JP2019506841A5 (enExample)
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP2016020389A5 (enExample)
JP2014518883A5 (enExample)
JP2019531093A5 (enExample)
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
JP2012000112A5 (enExample)
JP2010516708A5 (enExample)
JP2022119899A5 (enExample)
HRP20230078T1 (hr) Sredstva za vezivanje vegf/dll4 i njihova uporaba
JP2013539454A5 (enExample)
JP2005120106A5 (enExample)
JP2015525208A5 (enExample)
JP2008525033A5 (enExample)
WO2009103105A3 (en) Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders
JP2013539369A5 (enExample)
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ